Skip to main content

Triamcinolone Ophthalmic Dosage

Medically reviewed by Drugs.com. Last updated on Dec 20, 2021.

Applies to the following strengths: 40 mg/mL

Usual Adult Dose for Uveitis

4 mg (100 microliters of 40 mg/mL suspension) with subsequent dosage as needed over the course of treatment

Comments:

  • Strict aseptic technique is mandatory.
  • The vial should be vigorously shaken for 10 seconds before use.
  • Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).
  • After withdrawal, the suspension should be injected without delay.
  • Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause infection.

Uses:
  • Treatment of sympathetic ophthalmia
  • Treatment of temporal arteritis
  • Treatment of uveitis
  • Treatment of ocular inflammatory conditions unresponsive to topical

Usual Adult Dose for Temporal Arteritis

4 mg (100 microliters of 40 mg/mL suspension) with subsequent dosage as needed over the course of treatment

Comments:

  • Strict aseptic technique is mandatory.
  • The vial should be vigorously shaken for 10 seconds before use.
  • Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).
  • After withdrawal, the suspension should be injected without delay.
  • Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause infection.

Uses:
  • Treatment of sympathetic ophthalmia
  • Treatment of temporal arteritis
  • Treatment of uveitis
  • Treatment of ocular inflammatory conditions unresponsive to topical

Usual Adult Dose for Vitrectomy

1 to 4 mg (25 to 100 microliters of 40 mg/mL suspension) administered intravitreally

Comments:

  • Strict aseptic technique is mandatory.
  • The vial should be vigorously shaken for 10 seconds before use.
  • Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).
  • After withdrawal, the suspension should be injected without delay.
  • Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause infection.

Use: Visualization during vitrectomy

Usual Pediatric Dose for Uveitis

4 mg (100 microliters of 40 mg/mL suspension) with subsequent dosage as needed over the course of treatment

Comments:

  • Strict aseptic technique is mandatory.
  • The vial should be vigorously shaken for 10 seconds before use.
  • Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).
  • After withdrawal, the suspension should be injected without delay.
  • Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause infection.

Uses:
  • Treatment of sympathetic ophthalmia
  • Treatment of temporal arteritis
  • Treatment of uveitis
  • Treatment of ocular inflammatory conditions unresponsive to topical

Usual Pediatric Dose for Temporal Arteritis

4 mg (100 microliters of 40 mg/mL suspension) with subsequent dosage as needed over the course of treatment

Comments:

  • Strict aseptic technique is mandatory.
  • The vial should be vigorously shaken for 10 seconds before use.
  • Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).
  • After withdrawal, the suspension should be injected without delay.
  • Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause infection.

Uses:
  • Treatment of sympathetic ophthalmia
  • Treatment of temporal arteritis
  • Treatment of uveitis
  • Treatment of ocular inflammatory conditions unresponsive to topical

Usual Pediatric Dose for Vitrectomy

1 to 4 mg (25 to 100 microliters of 40 mg/mL suspension) administered intravitreally

Comments:

  • Strict aseptic technique is mandatory.
  • The vial should be vigorously shaken for 10 seconds before use.
  • Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).
  • After withdrawal, the suspension should be injected without delay.
  • Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause infection.

Use: Visualization during vitrectomy

Renal Dose Adjustments

Renal insufficiency: Use with caution

Liver Dose Adjustments

Data not available

Precautions

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • The manufacturer product information should be consulted.

Storage requirements:
  • Do not freeze.
  • Protect from light.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.